Poolbeg Pharma moves closer to obtaining US patent for flagship asset POLB 001
() , a clinical-stage biopharma company focused on infectious diseases, said it has received a Notice of Allowance from the US Patent Office in relation to its Immunomodulator II patent application. A Notice of Allowance is a precursor to a formal grant of a patent.
The claims cover a class of drugs, including POLB 001 - Poolbeg's flagship anti-inflammatory candidate - for the treatment and prevention of cytokine storm (hypercytokinaemia) after an immune response has been triggered. This encompasses cytokine storm induced in any disease indication.
The patent in progress marks a significant step for POLB 001, a potent and selective Phase II-ready p38 MAP kinase inhibitor (mitogen-activated protein kinase) which has shown strong potential across multiple disease areas. In November, Poolbeg was granted a similar patent for Immunomodulator II in Japan.
View from Vox
The Notice of Allowance from the US Patent Office represents a significant milestone for Poolbeg as it continues to build its IP portfolio. The company has a global license for POLB 001 and is actively building a comprehensive portfolio with patents in place, including Immunomodulator I and II, covering the use of the class of p38 MAP inhibitors for the treatment of severe influenza, and the use of POLB 001 for the treatment of hypercytokinaemia.
Today's announcement further highlights the progress Poolbeg has made in developing its patent portfolio, enhancing the value and attractiveness of its lead asset POLB 001 to potential pharma partners, particularly in respect of cancer immunotherapies. In response to the news, investors sent shares 6.04% higher in early trade on Wednesday.
POLB 001 has strong potential in making cancer immunotherapies more accessible by enabling their safer and broader use in an outpatient setting. The candidate has a compelling data package and targets unmet medical needs across several disease areas. POLB 001's potential to treat cancer immunotherapy-induced Cytokine Release Syndrome (CRS) alone has a market potential of US$10bn.
Follow News & Updates from Poolbeg Pharma:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.